Navigation Links
ClearTrial to Head Panel of Leading Wall Street Analysts at Pharmaceutical Accounting and Reporting Congress
Date:3/11/2010

Clinical Financial Best Practices Will Be Discussed and Demonstrated at Philadelphia Conference

Chicago, IL (PRWEB) March 11, 2010 -- ClearTrial, the leading provider of Clinical Trial Operations (CTO) software, today announced it will moderate a panel discussion which includes pharmaceutical analysts from Deutsche Bank and Cowen & Company at CBI's 2010 Accounting and Reporting Congress in Philadelphia, Pennsylvania, March 16-17. This conference is attended each year by over 300 finance, accounting, audit and reporting executives seeking information about changing regulations, technical accounting guidelines, auditing strategies and financial reporting best practices.

At this year's conference, participants will hear from an unparalleled assembly of over 35 speakers representing the pharmaceutical and biotechnology industries. Michael Bruns, CFO at ClearTrial, was chosen to moderate the Wall Street Panel, "Industry Performance Review and Strategies for Communicating Key Financial Information and Disclosures" on March 17th at 9:15 am. This panel discussion will provide perspectives from Wall Street on the pharmaceutical sector and key performance indicators. Attendees will learn best practices for investor calls, financial disclosures and overall communications regarding financial positions while gaining insight on industry trends and overall industry market perception from senior life science sector industry analysts.

Prior to joining ClearTrial, Mr. Bruns founded and directed the Technology and Investment Banking group at Robert W. Baird & Co., a global investment banking firm. He led the group's business development efforts and advised executive management teams and boards of directors of public and private company clients on corporate strategy, acquisition strategy and corporate finance alternatives.

Attendees can also visit ClearTrial in the exhibit hall to see practical demonstrations of how some of the world's leading Pharmaceutical and Biotech companies are using ClearTrial as the foundation for their innovative Clinical Financial Best Practices.

By attending these demonstrations, attendees will learn how to:

 
  • Accurately track accruals and reforecast for change orders
  • Gain insight into cost variances and underperforming projects
  • Determine when to outsource
  • Recognize cost savings within collaborative arrangements
  • Anticipate study costs for both in-licensing and out-licensing agreements

CBI's 2010 Accounting and Reporting Congress event will be held at the Loews Hotel, Philadelphia, PA on March 16-17. For more information and to register for the conference, visit http://www.cbinet.com/show_conference.cfm?confcode=PC10139.

About ClearTrial®
ClearTrial is the leading provider of Clinical Trial Operations (CTO) software, an integrated system for clinical operations planning, forecasting, outsourcing, and project tracking. ClearTrial's award-winning software helps life sciences companies streamline their clinical operations from Plan to Payment™ without sacrificing quality of results, providing executives and functional leaders in clinical operations, resource planning, finance, outsourcing, and project management with a common platform that promotes speed, accuracy, and consistency throughout the organization. For more information please visit http://www.cleartrial.com.

ClearTrial® and the ClearTrial logo are registered trademarks owned by ClearTrial, LLC, which may be registered in certain jurisdictions. Any other company or product names mentioned in this release are hereby acknowledged as registered trademarks or trademarks of their respective owners.

For more information contact:
Nicole Fitzmaurice
ClearTrial
+1 630.986.9800 x131
nfitzmaurice(at)cleartrial(dot)com

###

Read the full story at http://www.prweb.com/releases/2010/03/prweb3714124.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. ClearTrial Launches New Service to Bring Speed and Accuracy in Clinical Trial Planning Within Reach of Smaller Biopharma Companies
2. ClearTrial Selected to Provide Methodologies for Accurately Forecasting and Budgeting Clinical Spend and Integrated Financial Controls at CBI Conference
3. ClearTrial to Demonstrate Dramatic Gains in Clinical Outsourcing Efficiency Achieved by Biopharmaceutical Companies at European Outsourcing Event
4. ClearTrial Names Proven Enterprise Software and Life Sciences Sales Leader Craig Smith as Vice President of Sales
5. ClearTrial Launches Industry-first Software Platform for Integrating Clinical Trial Operations from Plan to Cash™, Driving Operational Efficiencies and Accelerating Clinical Development
6. ClearTrial Selected to Lead Executive Panel from Pharmaceutical and Service Provider Companies at ExL Conference
7. ClearTrial Industry Expert to Lead Session at DIA Annual Meeting on Improving Accrual and Contract Management in Clinical Trials
8. ClearTrial to Chair Session at DIA 45th Annual Meeting on "Effective Operational Planning for Adaptive Clinical Trials"
9. ClearTrial Names Software Industry Veteran Michael Bruns as Chief Operating Officer
10. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
11. ClearTrial Selected to Lead Industry Panel on Managing Clinical Trial Cash Flow and Accruals at CBI Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016 On Monday, the Department of ... to share solutions for the Biometric Exit Program. The ... Border Protection (CBP), explains that CBP intends to add ... the United States , in order to ... imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
Breaking Biology News(10 mins):